Annexon Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. Thank you for joining the 21st annual Needham healthcare conference. My name is Joey Stringer and I am one of the biotech analysts at Needham & Company. It's my pleasure to introduce our next presenting company, Annexon Biosciences. Joining us today from Annexon is President and CEO Doug love.
For those of you joining us on the webcast, if you wish to ask a question, please do so at any time. You can submit a question using the chat box at the bottom of your screen. So, with that we'll go ahead and get started. I'll turn it over to Doug for some brief opening remarks and then we'll go ahead and start with the chat.
Thanks so much, Joey. Really appreciate you and Needham having Annexon and myself with you this afternoon. Really excited about where we are as a company at this stage. I think you all are aware, we're focused on the classical pathway. And we are squarely in Phase 2/Phase 3 studies in multiple indications spanning autoimmune,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |